Peripheral Arterial Disease Trial, Recruiting NCT00598351 Sponsor: National Institute of Neurological Disorders and Stroke (NINDS) Condition: Peripheral Arterial Disease
Back to Peripheral Arterial Disease

Peripheral Arterial Disease Trial, Recruiting

NCT00598351
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have been diagnosed with Neurofibromatosis Type 2 (NF2), either through established medical criteria or genetic testing.
  • People aged between 8 and 75 years old.
  • People who are able to have repeated MRI scans of the brain and spine without needing sedation through a drip (IV).
  • People who are able to give their own informed consent to take part, or, for children, people whose parent is able to give consent on their behalf.

Who may not be able to join:

  • People who have a serious unstable medical condition that would make it unsafe to have regular check-ups and scans — for example, severe heart failure, severe long-term kidney disease, or severe long-term lung disease.
  • People who cannot have an MRI scan — for example, due to an allergy or concern about MRI contrast dye, or because they have metal implants in their body such as a pacemaker, stimulator, pump, aneurysm clip, metal prosthesis, or artificial heart valve that could cause harm or affect the scan images.
  • People who have an Auditory Brainstem Implant (ABI) or cochlear implant that has not been approved for safe use on the scanners at the NIH Radiology department.
  • People who have severe long-term kidney disease (based on a specific kidney function measurement), a condition called hepatorenal syndrome, or who have previously had a liver transplant.
  • People who are pregnant at the time of their first visit (women who could become pregnant will be asked to take a urine pregnancy test).

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 23 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Prashant Chittiboina, M.D., National Institute of Neurological Disorders and Stroke (NINDS)

Phone: (301) 496-2921

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
21 March 2008

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

To determine the natural history (clinical and radiographic) of nervous system tumors in NF2

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov